Literature DB >> 22039012

The connections between vascular calcification and bone health.

Jorge B Cannata-Andia, Pablo Roman-Garcia, Keith Hruska.   

Abstract

Vascular calcification, bone loss and increased fracture risk are age-associated disorders. Several epidemiological studies have suggested a relationship between vascular calcification, impaired bone metabolism and increased mortality. So far, this relationship had been under-estimated as osteoporosis and vascular calcification have been considered non-modifiable disorders of aging. Recent data suggest that this association is not simply an artefact of age, stressing that the co-incidence of vascular calcification with low bone activity and osteoporosis could be biologically linked. During the development of vascular calcification, the transition of vascular smooth muscle cells towards an osteoblast-like phenotype promotes the release of the vesicular structures and mineralization within these structures is promoted by several players, including those related to mineral metabolism, like phosphorus, calcium or parathyroid hormone, which influence either the supersaturation within the structure or the expression of osteogenic factors. However, an intriguing question is whether the presence of vascular calcification impacts bone metabolism, thus demonstrating true crosstalk between these tissues. Evidence is now emerging, suggesting that some inhibitors of the Wnt pathway, such as secreted frizzled Proteins 2 and 4 and Dickkopf related protein-1 (DKK-1), may play a role linking vascular calcification and bone loss. An additional important question to answer, from the patient's perspective, is whether or not progression of vascular calcification can be prevented or restricted and whether altering this progression we can efficiently impact patients' outcomes. Much evidence suggests that the control of the chronic kidney disease-mineral and bone disorder components, particularly serum phosphorus, are the main targets to maintain normal bone turnover and protect against vascular calcification.

Entities:  

Mesh:

Year:  2011        PMID: 22039012      PMCID: PMC4176055          DOI: 10.1093/ndt/gfr591

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  67 in total

1.  Bone mineral density and aortic calcification: the Study of Osteoporotic Fractures.

Authors:  M T Vogt; R San Valentin; K Y Forrest; M C Nevitt; J A Cauley
Journal:  J Am Geriatr Soc       Date:  1997-02       Impact factor: 5.562

2.  Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro.

Authors:  Hsueh Yang; Gabrielle Curinga; Cecilia M Giachelli
Journal:  Kidney Int       Date:  2004-12       Impact factor: 10.612

3.  Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6.

Authors:  Sheri L Holmen; Troy A Giambernardi; Cassandra R Zylstra; Bree D Buckner-Berghuis; James H Resau; J Fred Hess; Vaida Glatt; Mary L Bouxsein; Minrong Ai; Matthew L Warman; Bart O Williams
Journal:  J Bone Miner Res       Date:  2004-09-13       Impact factor: 6.741

Review 4.  Vascular calcification mechanisms.

Authors:  Cecilia M Giachelli
Journal:  J Am Soc Nephrol       Date:  2004-12       Impact factor: 10.121

Review 5.  Osteogenic regulation of vascular calcification: an early perspective.

Authors:  Radhika Vattikuti; Dwight A Towler
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-05       Impact factor: 4.310

6.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Authors:  Geoffrey A Block; Preston S Klassen; J Michael Lazarus; Norma Ofsthun; Edmund G Lowrie; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

7.  Osteoporosis and calcification of the aorta.

Authors:  M A Frye; L J Melton; S C Bryant; L A Fitzpatrick; H W Wahner; R S Schwartz; B L Riggs
Journal:  Bone Miner       Date:  1992-11

8.  The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study.

Authors:  T W O'Neill; D Felsenberg; J Varlow; C Cooper; J A Kanis; A J Silman
Journal:  J Bone Miner Res       Date:  1996-07       Impact factor: 6.741

9.  1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide.

Authors:  S Jono; Y Nishizawa; A Shioi; H Morii
Journal:  Circulation       Date:  1998-09-29       Impact factor: 29.690

10.  Arterial calcifications and bone histomorphometry in end-stage renal disease.

Authors:  Gérard M London; Caroline Marty; Sylvain J Marchais; Alain P Guerin; Fabien Metivier; Marie-Christine de Vernejoul
Journal:  J Am Soc Nephrol       Date:  2004-07       Impact factor: 10.121

View more
  28 in total

1.  Quantification of lower leg arterial calcifications by high-resolution peripheral quantitative computed tomography.

Authors:  Janina M Patsch; Martin A Zulliger; Nicolas Vilayphou; Elizabeth J Samelson; Daniel Cejka; Danielle Diarra; Gundula Berzaczy; Andrew J Burghardt; Thomas M Link; Michael Weber; Christian Loewe
Journal:  Bone       Date:  2013-08-14       Impact factor: 4.398

Review 2.  A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients.

Authors:  Dengpiao Xie; Naijing Ye; Mingquan Li
Journal:  Int Urol Nephrol       Date:  2018-01-02       Impact factor: 2.370

3.  Parathyroid hormone promotes osteoblastic differentiation of endothelial cells via the extracellular signal-regulated protein kinase 1/2 and nuclear factor-κB signaling pathways.

Authors:  Zhi-Yuan Cheng; Ting Ye; Qiu-Yang Ling; Ting Wu; Gang-Yong Wu; Gang-Jun Zong
Journal:  Exp Ther Med       Date:  2017-11-23       Impact factor: 2.447

Review 4.  Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho.

Authors:  Shunsuke Yamada; Cecilia M Giachelli
Journal:  Bone       Date:  2016-11-12       Impact factor: 4.398

Review 5.  From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.

Authors:  Vincent M Brandenburg; Patrick D'Haese; Annika Deck; Djalila Mekahli; Björn Meijers; Ellen Neven; Pieter Evenepoel
Journal:  Pediatr Nephrol       Date:  2015-03-04       Impact factor: 3.714

6.  Association of matrix Gla protein gene functional polymorphisms with loss of bone mineral density and progression of aortic calcification.

Authors:  D Tuñón-Le Poultel; J B Cannata-Andía; P Román-García; J B Díaz-López; E Coto; C Gómez; M Naves-Díaz; I Rodríguez
Journal:  Osteoporos Int       Date:  2013-11-27       Impact factor: 4.507

7.  Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4.

Authors:  Wei Lv; Lina Guan; Yan Zhang; Shengqiang Yu; Bofeng Cao; Yongqiang Ji
Journal:  Int Urol Nephrol       Date:  2016-07-27       Impact factor: 2.370

8.  Long-term proton pump inhibitor use is associated with vascular calcification in chronic kidney disease: a cross-sectional study using propensity score analysis.

Authors:  Maria Fusaro; Marianna Noale; Giovanni Tripepi; Sandro Giannini; Angela D'Angelo; Angelo Pica; Lorenzo A Calò; Davide Miozzo; Maurizio Gallieni
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

9.  Association of serum phosphorus variability with coronary artery calcification among hemodialysis patients.

Authors:  Mengjing Wang; Haiming Li; Li You; Xiaoling Yu; Min Zhang; Ruijiang Zhu; Chuanming Hao; Zhijie Zhang; Jing Chen
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

Review 10.  Therapy for patients with CKD and low bone mineral density.

Authors:  Susan M Ott
Journal:  Nat Rev Nephrol       Date:  2013-10-08       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.